WO2023062349A1 - Compositions à viscosité élevée - Google Patents

Compositions à viscosité élevée Download PDF

Info

Publication number
WO2023062349A1
WO2023062349A1 PCT/GB2022/052565 GB2022052565W WO2023062349A1 WO 2023062349 A1 WO2023062349 A1 WO 2023062349A1 GB 2022052565 W GB2022052565 W GB 2022052565W WO 2023062349 A1 WO2023062349 A1 WO 2023062349A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
mpa
powder
virus
signalling
Prior art date
Application number
PCT/GB2022/052565
Other languages
English (en)
Inventor
Lionel Scott
Samantha BOTTOMLEY
Peter Josling
Original Assignee
Nasaleze Patents Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nasaleze Patents Limited filed Critical Nasaleze Patents Limited
Publication of WO2023062349A1 publication Critical patent/WO2023062349A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/84—Valerianaceae (Valerian family), e.g. valerian
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9068—Zingiber, e.g. garden ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/148—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Definitions

  • a buccal cavity sensation may indicate that it is time to apply more of the composition to the nasal mucosa because the taste sensation within the buccal cavity may indicate that the cilia of the nasal mucosa have removed at least a portion of the applied composition from the nasal passages and into the throat and/or buccal cavity, from where it is then swallowed.
  • kits are also aimed at being used prophylactically to protect against viral attack from respiratory viruses as defined herein, such as influenza A viruses, for example, H1 N1 , H5N1 , and H3N2; and coronaviruses, such as MERS-CoV, SARS-CoV, HCoV-229E, HCov-NL63, HCoV-OC43, CoV-HKU1 , and SARS-COV-2; and mutants thereof.
  • respiratory viruses as defined herein, such as influenza A viruses, for example, H1 N1 , H5N1 , and H3N2; and coronaviruses, such as MERS-CoV, SARS-CoV, HCoV-229E, HCov-NL63, HCoV-OC43, CoV-HKU1 , and SARS-COV-2; and mutants thereof.
  • respiratory viruses as defined herein, such as influenza A viruses, for example, H1 N1 , H5N1 , and H
  • Vero A/T cells were seeded at 5x10 4 /well in 24-well plates 18 hours prior to use.
  • Cells were infected with SARS-CoV-2 (England-2) at an MOI of 1 or 0.01 and incubated for 30 min on a platform rocker at 37°C, 5% CO2.
  • Virus inoculum was removed, and cells washed twice with PBS and 150 pL/well of fresh 2%-DMEM added. To each well either 1 mg, 3 mg, or 6.4 mg of product was evenly distributed across the cell monolayer and incubated at room temperature for 15 min for gel-matrix formation to occur. Triplicate replicates were carried for each test conditions, and duplicate experiments were conducted. A no-product/plus virus control well was also established on each plate.
  • pHPMC used as a mechanical barrier against pollen in subjects with SAR also offers them protection against SARS-COV-2 infection.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

L'invention concerne des compositions de désactivation de virus respiratoire contenant des particules d'hydroxypropyl méthylcellulose (HPMC) en poudre ; et des agents de signalisation en poudre, présentant une viscosité moyenne comprise dans la plage allant de 26 000 mPa.s +/- 2000 mPa.S à 40 000 mPas +/5000 mPa.S à 20 °C dans une solution aqueuse de 3,6 %, des méthodes et des utilisations correspondantes.
PCT/GB2022/052565 2021-10-15 2022-10-10 Compositions à viscosité élevée WO2023062349A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB2114794.7A GB2611803A (en) 2021-10-15 2021-10-15 Compositions of high viscosity
GB2114794.7 2021-10-15

Publications (1)

Publication Number Publication Date
WO2023062349A1 true WO2023062349A1 (fr) 2023-04-20

Family

ID=78718502

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2022/052565 WO2023062349A1 (fr) 2021-10-15 2022-10-10 Compositions à viscosité élevée

Country Status (2)

Country Link
GB (1) GB2611803A (fr)
WO (1) WO2023062349A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1368090B1 (fr) 2001-02-08 2007-04-11 Nasaleze Patents Limited Appareil distributeur de matiere en poudre
US8202550B2 (en) 2004-10-11 2012-06-19 Nasaleze Ppm Limited Compositions for intranasal administration
EP3183022B1 (fr) 2014-08-20 2019-09-04 Nasaleze Patents Ltd Appareil de distribution
EP3154515B1 (fr) 2014-06-10 2021-04-28 Nasaleze Patents Limited Améliorations apportées à des compositions nasales et méthode d'utilisation associée
WO2021160982A1 (fr) * 2020-02-12 2021-08-19 Nasaleze Patents Limited Compositions et leurs applications

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1368090B1 (fr) 2001-02-08 2007-04-11 Nasaleze Patents Limited Appareil distributeur de matiere en poudre
US8202550B2 (en) 2004-10-11 2012-06-19 Nasaleze Ppm Limited Compositions for intranasal administration
EP3154515B1 (fr) 2014-06-10 2021-04-28 Nasaleze Patents Limited Améliorations apportées à des compositions nasales et méthode d'utilisation associée
EP3183022B1 (fr) 2014-08-20 2019-09-04 Nasaleze Patents Ltd Appareil de distribution
WO2021160982A1 (fr) * 2020-02-12 2021-08-19 Nasaleze Patents Limited Compositions et leurs applications

Non-Patent Citations (22)

* Cited by examiner, † Cited by third party
Title
COLE, E. C.COOK, C. E.: "Characterization of infectious aerosols in health care facilities: an aid to effective engineering controls and preventive strategies", AM J INFECT CONTROL, vol. 26, no. 4, 1998, pages 453 - 64, XP005697684, DOI: 10.1016/S0196-6553(98)70046-X
FENNELLY, K. P.: "Particle sizes of infectious aerosols: implications for infection control", LANCET RESPIR MED, vol. 8, no. 9, 2020, pages 914 - 924
HAN, Z. Y.WENG, W. G.HUANG, Q. Y.: "Characterizations of particle size distribution of the droplets exhaled by sneeze", J R SOC INTERFACE, vol. 10, no. 88, 2013, pages 20130560
HEMILA, H.CHALKER, E.: "Carrageenan nasal spray may double the rate of recovery from coronavirus and influenza virus infections: Re-analysis of randomized trial data", PHARMACOL RES PERSPECT, vol. 9, no. 4, 2021, pages e00810
HILTUNEN RAIMO ET AL: "Preventing airborne infection with an intranasal cellulose powder formulation (Nasaleze Travel )", ADVANCES IN THERAPY, HEALTH COMMUNICATIONS, METUCHEN, NJ, US, vol. 24, no. 5, 1 September 2007 (2007-09-01), pages 1146 - 1153, XP037069078, ISSN: 0741-238X, DOI: 10.1007/BF02877720 *
HUNT, N.SULEMAN, L.JOSLING, P. D.POPOV, T.: "Virucidal activity of Nasaleze Cold and Flu Blocker and Nasaleze Travel in cell cultures infected with human pathogenic coronavirus 229-E", BIORXIV, 2021
JANG, Y.SHIN, H.LEE, M. K.KWON, O. S.SHIN, J. S.KIM, Y. I.KIM, C. W.LEE, H. R.KIM, M.: "Antiviral activity of lambda-carrageenan against influenza viruses and severe acute respiratory syndrome coronavirus 2", SCI REP, vol. 11, no. 1, 2021, pages 821
LEIBBRANDT, A.MEIER, C.KONIG-SCHUSTER, M.WEINMULLNER, R.KALTHOFF, D.PFLUGFELDER, B.GRAF, P.FRANK-GEHRKE, B.BEER, M.FAZEKAS, T.: "Iota-carrageenan is a potent inhibitor of influenza A virus infection", PLOS ONE, vol. 5, no. 12, 2010, pages e14320, XP009159153, DOI: 10.1371/journal.pone.0014320
LVOV DKDERYABIN PG: "Virucidal Activity of Nasaleze (Nasaval) and Nasaleze Travel (Nasaleze Plus) in Cell Cultures Infected with Pathogenic Avian Flu virus (H5N1", EUROPEAN JOURNAL FOR NUTRACEUTICAL RESEARCH, 2010, pages 1 - 8, Retrieved from the Internet <URL:www.phytomedcentral.org>
MOAKES, R. J. A.; DAVIES, S. P.; STAMATAKI, Z.; GROVER, L. M.: "Formulation of a Composite Nasal Spray Enabling Enhanced Surface Coverage and Prophylaxis of SARS-COV-2", ADV MATER, 2021, pages e2008304
MORAWSKA, L.CAO, J.: "Airborne transmission of SARS-CoV-2: The world should face the reality", ENVIRON INT, vol. 139, 2020, pages 105730, XP086155362, DOI: 10.1016/j.envint.2020.105730
MOROKUTTI-KURZ, M.FROBA, M.GRAF, P.GROBE, M.GRASSAUER, A.AUTH, J.SCHUBERT, U.PRIESCHL-GRASSAUER, E.: "Iota-carrageenan neutralizes SARS-CoV-2 and inhibits viral replication in vitro", PLOS ONE, vol. 16, no. 2, 2021, pages e0237480
POPOV T.A. ET AL., EXPERT REVIEW OF RESPIRATORY MEDICINE, vol. 11, no. 11, 2017, pages 885 - 892, Retrieved from the Internet <URL:https://doi.org/10.1080/17476348.2017.1375408>
POPOV, T. A.ABERG, N.EMBERLIN, J.JOSLING, P.ILYINA, N. I.NIKITIN, N. P.CHURCH, M.: "Methyl-cellulose powder for prevention and management of nasal symptoms", EXPERT REV RESPIR MED, vol. 11, no. 11, 2017, pages 885 - 892, XP055810278, DOI: 10.1080/17476348.2017.1375408
POPOV, T. AEMBERLIN, J.JOSLING, P.SEIFALIAN, A.: "In vitro and in vivo Evaluation of the Efficacy and Safety of Powder Hydroxypropylmethylcellulose as Nasal Mucosal Barrier", MED DEVICES (AUCKL, vol. 13, 2020, pages 107 - 113, XP055804081, DOI: 10.2147/MDER.S236104
PROCTOR, D. F.LUNDQVIST, G.: "Clearance of inhaled particles from the human nose", ARCH INTERN MED, vol. 131, no. 1, 1973, pages 132 - 9
SCHUTZ, D.CONZELMANN, C.FOIS, G.GROB, R.WEIL, T.WETTSTEIN, L.STENGER, S.ZELIKIN, A.HOFFMANN, T. K.FRICK, M.: "Carrageenan-containing over-the-counter nasal and oral sprays inhibit SARS-CoV-2 infection of airway epithelial cultures", AM J PHYSIOL LUNG CELL MOL PHYSIOL, vol. 320, no. 5, 2021, pages L750 - L756
STADNYTSKYI, V.; BAX, C. E.; BAX, A.; ANFINRUD, P.: "The airborne lifetime of small speech droplets and their potential importance in SARS-CoV-2 transmission", PROC NATL ACAD SCI U S A, vol. 117, no. 22, 2020, pages 11875 - 11877
TELLIER, R.LI, Y.COWLING, B. J.TANG, J. W.: "Recognition of aerosol transmission of infectious agents: a commentary", BMC INFECT DIS, vol. 19, no. 1, 2019, pages 101, XP021270762, DOI: 10.1186/s12879-019-3707-y
WINCHESTER, S.JOHN, S.JABBAR, K.JOHN, I.: "Clinical efficacy of nitric oxide nasal spray (NONS) for the treatment of mild COVID-19 infection", J INFECT, vol. 83, no. 2, 2021, pages 237 - 279, XP086703299, DOI: 10.1016/j.jinf.2021.05.009
ZHANG, R.LI, Y.ZHANG, A. L.WANG, Y.MOLINA, M. J.: "Identifying airborne transmission as the dominant route for the spread of COVID-19", PROC NATL ACAD SCI U S A, vol. 117, no. 26, 2020, pages 14857 - 14863, XP055822961, DOI: 10.1073/pnas.2009637117
ZIA, K. M.TABASUM, S.NASIF, M.SULTAN, N.ASLAM, N.NOREEN, A.ZUBER, M.: "A review on synthesis, properties and applications of natural polymer based carrageenan blends and composites", INT J BIOL MACROMOL, vol. 96, 2017, pages 282 - 301, XP029886066, DOI: 10.1016/j.ijbiomac.2016.11.095

Also Published As

Publication number Publication date
GB2611803A (en) 2023-04-19
GB202114794D0 (en) 2021-12-01

Similar Documents

Publication Publication Date Title
Schütz et al. Carrageenan-containing over-the-counter nasal and oral sprays inhibit SARS-CoV-2 infection of airway epithelial cultures
Whitley Smallpox: a potential agent of bioterrorism
Huijghebaert et al. Essentials in saline pharmacology for nasal or respiratory hygiene in times of COVID-19
US20200384016A1 (en) Prevention of infection by highly pathogenic viruses using topical application of povidone-iodine on mucous membranes
US20230075885A1 (en) Compositions and applications thereof
Upadhayay et al. Frequently used allopathic and traditional medicine for COVID-19 treatment and feasibility of their integration
CA3172672A1 (fr) Composition pharmaceutique pour prevenir ou traiter une maladie infectieuse epidemique a virus a arn
CN116056714A (zh) 预防冠状病毒及/或呼吸道融合病毒感染的方法
WO2023062349A1 (fr) Compositions à viscosité élevée
Malani et al. Repurposing pharmaceutical excipients as an antiviral agent against SARS-CoV-2
Go et al. Intranasal therapy and COVID-19: A comprehensive literature review
WO2024096743A1 (fr) Anticorps de liaison au sars-cov-2
AU2020102610A4 (en) Prevention of infection by highly pathogenic viruses using topical application of povidone-iodine on mucous membranes
EP4082528A1 (fr) Formulation de pulvérisation de liquide
US20230270839A1 (en) Vaccine compositions
SE2151572A1 (en) Pharmaceutical composition for treatment of viral infections caused by enveloped viruses
Tiwari Prevention of Transmission of COVID-19
Wettstein et al. Carrageenan containing over-the-counter nasal and oral sprays inhibit SARS-CoV-2 infection of airway epithelial cultures 2
WO2021186435A1 (fr) Compositions polymères pour administration intranasale
CN116096366A (zh) 植物化学物质组合物
WO2022214671A1 (fr) Composition pharmaceutique pour la prévention ou le traitement d&#39;une maladie induite par virus
WO2023104327A1 (fr) Combinaison de 5-amino-2,3-dihydro-1,4-phtalazinedione et d&#39;un 6&#39;-méthoxycinchonane-9-ol pour une utilisation dans le traitement d&#39;infections coronavirales
OA21043A (en) Pharmaceutical composition for preventing or treating epidemic RNA viral infectious disease.
Kumar et al. Role of Pineapple and its Bioactive Compound Bromelain in COVID 19
WO2024096742A1 (fr) Polypeptide de liaison au sars-cov-2

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22790347

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE